On Tuesday, TD Cowen maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) shares with an unchanged price target of $85.00. The firm's recent model update for Gilead Sciences, which trades on NASDAQ:GILD, factored in adjustments ahead of the company's second-quarter earnings for 2024.
The adjustments included an increase in the total HIV and liver disease revenue estimates, while projections for cell therapy and Veklury, a treatment previously used for COVID-19, were reduced.
The revised model by TD Cowen now estimates a non-GAAP earnings per share (EPS) of $1.80 for Gilead Sciences in the second quarter of 2024. Despite the changes in revenue projections for different segments of the company's portfolio, TD Cowen has decided to maintain the current discounted cash flow (DCF) analysis, which supports the firm's valuation and consequent price target.
The updated estimates come as part of TD Cowen Biotech's broader second-quarter earnings preview. The firm's analysis reflects a detailed assessment of Gilead's financial prospects based on recent developments within the company's diverse therapeutic areas. The adjustments in the revenue estimates indicate a shift in the expected performance of the company's key products.
Gilead Sciences has been a prominent player in the biopharmaceutical industry, with a strong focus on life-threatening diseases such as HIV and liver diseases. The company's portfolio also extends to novel cell therapies, which have been a significant area of investment and innovation.
TD Cowen's affirmation of the Buy rating and price target suggests confidence in Gilead Sciences' business strategy and future earnings potential. The firm's analysis is based on the latest available financial data and projections, providing investors with a snapshot of the company's anticipated performance as it approaches its next earnings report.
In other recent news, Gilead Sciences has been the focus of significant developments. Raymond James upgraded Gilead Sciences' stock to Outperform due to promising data from the PURPOSE-1 study of lenacapavir, an HIV pre-exposure prophylaxis drug, and the expected approval of seladelpar for primary biliary cholangitis. The firm projects these two drugs could contribute $3.7 billion to Gilead's revenue by 2030.
Simultaneously, RBC Capital maintained a Sector Perform rating on Gilead's shares, citing lenacapavir's potential to expand the overall market. Despite potential limitations, RBC Capital estimates that lenacapavir could generate approximately $2 billion in global revenue by the early 2030s.
In addition, Gilead's Phase 3 trial of lenacapavir achieved a 100% efficacy rate with no new HIV infections reported among participants. The company also anticipates additional results from the PURPOSE 2 trial by late 2024 or early 2025.
Furthermore, Evercore ISI maintained an Outperform rating on Gilead's shares based on promising preclinical data on the company's investigational oral GLP-1 agonist, GS-4571. BMO Capital Markets also sustained its Outperform rating for Gilead, despite setbacks in oncology, and highlighted potential approval of seladelpar for Primary Biliary Cholangitis patients.
InvestingPro Insights
In light of TD Cowen's recent analysis, it's notable that Gilead Sciences (NASDAQ:GILD) has demonstrated a commitment to shareholder returns, having raised its dividend for 9 consecutive years. This consistency is reflected in the company's current dividend yield of 4.25%, showcasing its appeal to income-focused investors.
Moreover, Gilead's valuation suggests a strong free cash flow yield, which may indicate an attractive entry point for value investors, especially considering the firm's prominent standing in the biotechnology industry.
From a financial standpoint, Gilead Sciences boasts a market capitalization of $90.21 billion and a healthy gross profit margin of 77.52% over the last twelve months as of Q1 2024. The company's revenue growth for the same period stands at 1.51%, with an even more impressive quarterly revenue growth of 5.26% in Q1 2024. These metrics, together with the company's operating income margin of 36.15%, paint a picture of a robust financial entity capable of weathering market fluctuations and investing in future growth.
For investors seeking a deeper dive into Gilead Sciences' financial health and future prospects, there are additional InvestingPro Tips available, which can be accessed by visiting https://www.investing.com/pro/GILD.
Moreover, those interested in a comprehensive analysis can take advantage of an exclusive offer using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. With 7 more tips to uncover, including insights on earnings multiples and stock volatility, InvestingPro provides a more granulated view of Gilead's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.